| David Meranda, MD | |
|
1 Akron General Ave, Akron, OH 44307 | |
| (330) 344-6000 | |
| Not Available |
| Full Name | David Meranda |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 1 Akron General Ave, Akron, Ohio |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811383102 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 35.132879 (Ohio) | Primary |
| Entity Name | University Emergency Specialists Of Bedford Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760434781 PECOS PAC ID: 2466357801 Enrollment ID: O20031126000765 |
News Archive
To address surgeons' need for achieving strong vessel seals while remaining gentle on tissue in open surgery, Ethicon Endo-Surgery, Inc. (EES) today announces the launch of its innovative ENSEAL® G2 Super Jaw advanced bipolar technology.
A simple test which can detect gene mutations in tumour DNA from blood samples is giving new choices to lung cancer patients with faster diagnosis and improved access to life changing drugs.
Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose "Quad" regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.
Japanese researchers are inspired by a brainless primeval organism – yellow amoeboid slime, to devise the ideal transport network design.
› Verified 8 days ago
| Entity Name | Emergency Medicine Physicians Of Cuyahoga County, Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265471148 PECOS PAC ID: 1153216965 Enrollment ID: O20040219000948 |
News Archive
To address surgeons' need for achieving strong vessel seals while remaining gentle on tissue in open surgery, Ethicon Endo-Surgery, Inc. (EES) today announces the launch of its innovative ENSEAL® G2 Super Jaw advanced bipolar technology.
A simple test which can detect gene mutations in tumour DNA from blood samples is giving new choices to lung cancer patients with faster diagnosis and improved access to life changing drugs.
Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose "Quad" regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.
Japanese researchers are inspired by a brainless primeval organism – yellow amoeboid slime, to devise the ideal transport network design.
› Verified 8 days ago
| Entity Name | Physicians Link Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235172925 PECOS PAC ID: 8527969492 Enrollment ID: O20040405000838 |
News Archive
To address surgeons' need for achieving strong vessel seals while remaining gentle on tissue in open surgery, Ethicon Endo-Surgery, Inc. (EES) today announces the launch of its innovative ENSEAL® G2 Super Jaw advanced bipolar technology.
A simple test which can detect gene mutations in tumour DNA from blood samples is giving new choices to lung cancer patients with faster diagnosis and improved access to life changing drugs.
Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose "Quad" regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.
Japanese researchers are inspired by a brainless primeval organism – yellow amoeboid slime, to devise the ideal transport network design.
› Verified 8 days ago
| Entity Name | Ues Richmond Heights Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568414613 PECOS PAC ID: 8224057047 Enrollment ID: O20051122000004 |
News Archive
To address surgeons' need for achieving strong vessel seals while remaining gentle on tissue in open surgery, Ethicon Endo-Surgery, Inc. (EES) today announces the launch of its innovative ENSEAL® G2 Super Jaw advanced bipolar technology.
A simple test which can detect gene mutations in tumour DNA from blood samples is giving new choices to lung cancer patients with faster diagnosis and improved access to life changing drugs.
Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose "Quad" regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.
Japanese researchers are inspired by a brainless primeval organism – yellow amoeboid slime, to devise the ideal transport network design.
› Verified 8 days ago
| Entity Name | Ues Geauga, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841242997 PECOS PAC ID: 6406876002 Enrollment ID: O20051128000779 |
News Archive
To address surgeons' need for achieving strong vessel seals while remaining gentle on tissue in open surgery, Ethicon Endo-Surgery, Inc. (EES) today announces the launch of its innovative ENSEAL® G2 Super Jaw advanced bipolar technology.
A simple test which can detect gene mutations in tumour DNA from blood samples is giving new choices to lung cancer patients with faster diagnosis and improved access to life changing drugs.
Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose "Quad" regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.
Japanese researchers are inspired by a brainless primeval organism – yellow amoeboid slime, to devise the ideal transport network design.
› Verified 8 days ago
| Entity Name | University Emergency Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033454483 PECOS PAC ID: 4587807854 Enrollment ID: O20130905000711 |
News Archive
To address surgeons' need for achieving strong vessel seals while remaining gentle on tissue in open surgery, Ethicon Endo-Surgery, Inc. (EES) today announces the launch of its innovative ENSEAL® G2 Super Jaw advanced bipolar technology.
A simple test which can detect gene mutations in tumour DNA from blood samples is giving new choices to lung cancer patients with faster diagnosis and improved access to life changing drugs.
Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose "Quad" regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.
Japanese researchers are inspired by a brainless primeval organism – yellow amoeboid slime, to devise the ideal transport network design.
› Verified 8 days ago
| Entity Name | Ues Ahuja Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467883934 PECOS PAC ID: 5496985467 Enrollment ID: O20140313001425 |
News Archive
To address surgeons' need for achieving strong vessel seals while remaining gentle on tissue in open surgery, Ethicon Endo-Surgery, Inc. (EES) today announces the launch of its innovative ENSEAL® G2 Super Jaw advanced bipolar technology.
A simple test which can detect gene mutations in tumour DNA from blood samples is giving new choices to lung cancer patients with faster diagnosis and improved access to life changing drugs.
Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose "Quad" regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.
Japanese researchers are inspired by a brainless primeval organism – yellow amoeboid slime, to devise the ideal transport network design.
› Verified 8 days ago
| Entity Name | Magis Emergency Medicine, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801287511 PECOS PAC ID: 2769700392 Enrollment ID: O20150410002555 |
News Archive
To address surgeons' need for achieving strong vessel seals while remaining gentle on tissue in open surgery, Ethicon Endo-Surgery, Inc. (EES) today announces the launch of its innovative ENSEAL® G2 Super Jaw advanced bipolar technology.
A simple test which can detect gene mutations in tumour DNA from blood samples is giving new choices to lung cancer patients with faster diagnosis and improved access to life changing drugs.
Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose "Quad" regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.
Japanese researchers are inspired by a brainless primeval organism – yellow amoeboid slime, to devise the ideal transport network design.
› Verified 8 days ago
| Entity Name | Usacs Observation Medicine Services Of Ohio, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649947151 PECOS PAC ID: 7911398789 Enrollment ID: O20220105001713 |
News Archive
To address surgeons' need for achieving strong vessel seals while remaining gentle on tissue in open surgery, Ethicon Endo-Surgery, Inc. (EES) today announces the launch of its innovative ENSEAL® G2 Super Jaw advanced bipolar technology.
A simple test which can detect gene mutations in tumour DNA from blood samples is giving new choices to lung cancer patients with faster diagnosis and improved access to life changing drugs.
Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose "Quad" regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.
Japanese researchers are inspired by a brainless primeval organism – yellow amoeboid slime, to devise the ideal transport network design.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Meranda, MD 1 Akron General Ave, Akron, OH 44307-2432 Ph: () - | David Meranda, MD 1 Akron General Ave, Akron, OH 44307 Ph: (330) 344-6000 |
News Archive
To address surgeons' need for achieving strong vessel seals while remaining gentle on tissue in open surgery, Ethicon Endo-Surgery, Inc. (EES) today announces the launch of its innovative ENSEAL® G2 Super Jaw advanced bipolar technology.
A simple test which can detect gene mutations in tumour DNA from blood samples is giving new choices to lung cancer patients with faster diagnosis and improved access to life changing drugs.
Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose "Quad" regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.
Japanese researchers are inspired by a brainless primeval organism – yellow amoeboid slime, to devise the ideal transport network design.
› Verified 8 days ago
Dr. Jason Dean Eidahl, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 525 E Market St, Akron, OH 44304 Phone: 330-375-3000 | |
Sharhabeel Jwayyed, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 525 E Market St, Akron, OH 44304 Phone: 330-375-3369 Fax: 330-375-3769 | |
Ryan James Reichert, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1 Perkins Square, Akron Childrens Hospital, Akron, OH 44302 Phone: 330-543-1000 | |
Jack H Mitstifer, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 Wabash Ave, Akron, OH 44307 Phone: 330-344-1799 Fax: 330-253-8293 | |
Mary Jo Mcmullen, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 400 Wabash Ave, Akron, OH 44307 Phone: 330-344-1799 Fax: 330-253-8293 | |
Carlynn Fulp, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Akron General Ave, Akron, OH 44307 Phone: 330-344-6000 | |
Gregory Mancini, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Akron General Ave, Akron, OH 44307 Phone: 330-344-6000 |